Report Highlights

The U.S. Role in the Global Maternity and Personal Care Supply Chain

The United States is the largest end-consumer of maternity and personal care products globally but a net importer of nearly all finished maternity apparel. Roughly 90 percent of maternity garments sold in the U.S. are sourced from China, Vietnam, Bangladesh, and India, routed mainly through the Ports of Los Angeles and Long Beach. Domestic manufacturing concentrates in breast pumps and lactation devices, where Medela's McHenry, Illinois facility anchors a value-added hub serving North American demand.

Personal care inputs such as topical emollients, stretch-mark creams, and perineal care products rely on imported active ingredients, notably specialty oils and surfactants from Southeast Asia and Europe. Export flows are modest, with U.S. lactation and infant-feeding device shipments going mainly to Canada, Mexico, and Japan. The strategic vulnerability lies in concentrated sourcing of medical-grade plastics for pump components, which passes through a narrow set of Asian suppliers before reaching domestic assembly.

Growth Drivers for U.S. Maternity and Personal Care Trade and Production

Domestic production capacity is expanding in lactation technology, where Medela and Ameda are scaling assembly in the Midwest and Southeast to shorten lead times for hospital-grade pumps. Insurance coverage mandates under the Affordable Care Act have pulled volume into durable medical equipment channels and justified automated production lines. Import substitution is most visible here, as payer-approved pumps increasingly ship from U.S. warehouses rather than Asian contract manufacturers.

Export growth is rising in personal care, where U.S.-formulated prenatal skincare brands use contract filling facilities in Canada and Mexico to serve Latin American distributors under USMCA preferences. Reshoring of intimate apparel cutting and sewing, supported by digital cutting technology, is testing the cost curve in Georgia and North Carolina. Demand for postpartum recovery garments is also lifting domestic textile converters that supply compression fabric.

Supply Chain Risks and Trade Barriers

Tariff exposure is the dominant risk. Section 301 duties on Chinese-origin apparel and textiles, alongside reciprocal tariffs introduced in 2025 on Vietnamese and Bangladeshi goods, raise landed costs for maternity garments beyond what retailers can fully pass through. Gap Inc. and its Old Navy maternity line have shifted sourcing toward Central America, although that transition extends lead times to 90 to 120 days from order.

Logistics fragility compounds the problem. The Ports of Los Angeles and Long Beach handle most containerized maternity imports, and labor disputes or congestion at either terminal create multi-week delays for seasonal inventory. Currency risk also affects imported medical-grade components priced in euros and Swiss francs, exposing buyers to sudden cost swings. Pump supply interruptions in 2022 demonstrated how a single supplier failure cascades through hospital and retail channels.

Trade and Investment Opportunities in the U.S.

Import substitution in breast pump components offers an investable gap. Domestic injection molding for flange and valve parts, currently sourced from Germany and South Korea, can serve the roughly 3.6 million annual U.S. births more efficiently with nearshored capacity in Ohio or Tennessee. Investors with existing medical device contract manufacturing platforms can capture payer reimbursement volume without tariff exposure on finished goods.

Export opportunity exists in outbound personal care formulations to Gulf Cooperation Council markets and South Korea, where American prenatal skincare brands command premium positioning. A logistics hub in Savannah or Houston combining cold-chain warehousing and bonded storage would allow brands to stage inventory for multi-market distribution. Direct-to-consumer brands with fulfilment in Texas reduce transit times to Mexico and the wider Latin American network.

Market at a Glance

Leading Market Participants

• Medela
• Motherhood Maternity
• Pea in the Pod
• Ingrid & Isabel
• Gap Inc.
• Hatch Baby
• Philips Avent
• Ameda
• Johnson & Johnson
• Procter & Gamble

Regulatory and Trade Policy Environment

The U.S. framework is governed by the Harmonized Tariff Schedule, with apparel subject to duties that vary by fiber content and country of origin. Textile imports from China face Section 301 tariffs, and the Uyghur Forced Labor Prevention Act requires importers to demonstrate supply chain traceability for cotton-based maternity garments. U.S. Customs and Border Protection actively detains shipments that lack documented origin evidence.

Breast pumps fall under FDA Class II device regulation, requiring 510(k) clearance and Quality System Regulation compliance for domestic and imported units. The USMCA governs duty-free flows among the U.S., Mexico, and Canada, with rules of origin requiring regional content for textiles. State economic development incentives in Ohio and Tennessee further reward qualifying medical device plant construction.

U.S. Maternity and Personal Care Supply Chain Outlook to 2032

Through 2032, the U.S. position will shift from import dependence toward regional sourcing. Apparel will continue relying on Asian production for specialty fabrics but migrate assembly toward Central American and Caribbean Basin facilities under CAFTA-DR preferences. Breast pump and lactation device manufacturing will consolidate into automated U.S. facilities, reducing dependence on Swiss and Korean component inputs.

Technology will alter comparative advantage. Digital textile printing, 3D body scanning for fit, and bio-based polymers will reduce the cost penalty of domestic production for maternity garments. Smart breast pumps with embedded sensors will raise value-added assembly rather than volume output, favoring firms with software and regulatory capability in Massachusetts and California.